This document is an excerpt from the EUR-Lex website
Document 52012XG0718(01)
Council conclusions of 22 June 2012 on the impact of antimicrobial resistance in the human health sector and in the veterinary sector — a ‘One Health’ perspective
Council conclusions of 22 June 2012 on the impact of antimicrobial resistance in the human health sector and in the veterinary sector — a ‘One Health’ perspective
Council conclusions of 22 June 2012 on the impact of antimicrobial resistance in the human health sector and in the veterinary sector — a ‘One Health’ perspective
SL C 211, 18.7.2012, p. 2–5
(BG, ES, CS, DA, DE, ET, EL, EN, FR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)
18.7.2012 |
EN |
Official Journal of the European Union |
C 211/2 |
Council conclusions of 22 June 2012 on the impact of antimicrobial resistance in the human health sector and in the veterinary sector — a ‘One Health’ perspective
2012/C 211/02
THE COUNCIL OF THE EUROPEAN UNION
1. |
RECALLS the Council conclusions of 10 June 2008 on antimicrobial resistance (AMR) (1). |
2. |
RECALLS the Council conclusions of 23 November 2009 on innovative incentives for effective antibiotics (2). |
3. |
RECALLS the Council Recommendation of 15 November 2001 on the prudent use of antimicrobial agents in human medicine (3), including the reports of December 2005 and April 2010 from the Commission to the Council on its implementation (4). |
4. |
RECALLS the Council Recommendation of 9 June 2009 on patient safety, including the prevention and control of healthcare associated infections (5). |
5. |
ACKNOWLEDGES the Scientific Opinion of October 2009 of the European Centre for Disease Prevention and Control (ECDC), the European Food Safety Authority (EFSA), the European Medicines Agency (EMA) and the Scientific Committee on Emerging and Newly Identified Health Risks (SCENIHR) on antimicrobial resistance focused on zoonotic infections (6). |
6. |
ACKNOWLEDGES the European Parliament Resolution of 5 May 2010 on evaluation and assessment of Animal Welfare Action Plan 2006-2010 (7). |
7. |
RECALLS the European Parliament Resolutions of 12 May 2011 on antibiotic resistance (8) and of 27 October 2011 on the public health threat of antimicrobial resistance (9). |
8. |
WELCOMES the European Commission Communication of 15 November 2011 on an action plan against the rising threats from Antimicrobial Resistance (10). |
9. |
RECALLS the Regulation (EC) No 1831/2003 of the European Parliament and of the Council of 22 September 2003 on additives for use in animal nutrition prohibiting the use of antibiotic growth promoters (11). |
10. |
STRESSES that AMR is a growing European and global health problem in both humans and animals, leading to limited or poor options for treatment whilst diminishing the quality of life and to important economic consequences in terms of augmenting healthcare costs and productivity losses. |
11. |
RECOGNISES that the development of AMR is accelerated by excessive and inappropriate use of antimicrobial agents which, together with poor hygiene or poor infection control practices, creates favourable conditions for the development, spread and persistence of resistant micro-organisms in both humans and animals. |
12. |
RECOGNISES that there are varying situations and different approaches in prescription, use and distribution of antimicrobials in the Member States, including types of antimicrobials used, in human medicine and in veterinary medicine. |
13. |
UNDERLINES the need for an active holistic risk based approach based on a ‘One Health’ perspective with the purpose of reducing the use of antimicrobials as much as possible and to maximise coordinated efforts between the human health sector and the veterinary sector in the fight against AMR. |
14. |
STRESSES that microbiological diagnosis together with standardised susceptibility testing create the basis for a correct choice of antimicrobial treatment and de-escalation of the initial empirical treatment, thus allowing antimicrobials to be used in the most appropriate way with the objective to limiting the use of antimicrobials in general and especially of critically important antimicrobials (CIAs). |
15. |
ACKNOWLEDGES the definitions of CIAs for humans and animals by the World Health Organisation (WHO) and the World Organisation for Animal Health (OIE), respectively, as the basis for European efforts. |
16. |
STRESSES the need to target the use of CIAs to specific cases in which the use is considered appropriate. |
17. |
STRESSES the need to be restrictive in both the human and veterinary use of CIAs and newly developed antimicrobials, eventually with the aim in the future to reserve CIAs as much as possible for human use. |
18. |
STRESSES the need for all Member States to require that, as a minimum, oral, inhaled and parenteral antimicrobial agents are only available through prescription or in clearly defined circumstances, under the supervision of a regulated health care professional. |
19. |
RECOGNISES that some practises in human and in animal healthcare including the possible incentives deriving from the prescription and subsequent sale of antimicrobial agents may lead to inappropriate use and overuse of antimicrobial agents. |
20. |
STRESSES the importance of effective surveillance systems in both the human health sector and the veterinary sector based on existing monitoring systems under the auspices of EFSA, the ECDC European Surveillance of Antimicrobial Consumption Network (ESAC-net), the ECDC European Antimicrobial Resistance Surveillance Network (EARS-net), and the EMA European Surveillance of Veterinary Antimicrobial Consumption (ESVAC) to allow collection of comparable and timely data on AMR and on the use of antimicrobial agents. |
21. |
RECOGNISES the importance of EU support through existing EU financial instruments such as the Health Programme and the EU Framework Programme for Research and Innovation including the Innovative Medicine Initiative (IMI) to improve research and development on AMR and strengthen prevention and control against AMR and the need to continue these activities and implementing the results. |
22. |
STRESSES the importance of enhancing the coordination of Member States research activities on countering AMR in the EU (12). |
23. |
STRESSES the need to actively raise awareness in the general public, and in the human health sector and veterinary sector about the risks of AMR due to excessive and inappropriate use of antimicrobial agents and the consequences of AMR for the individual and society in general and, RECOGNISES the importance of the European Antibiotic Awareness Day as a platform for national awareness campaigns. |
24. |
STRESSES the importance of continuous training and education of human health and veterinary professionals in the diagnosis, treatment and prevention of infectious diseases and in the appropriate use of antimicrobials and where relevant, continuous training and education in prevention of infectious diseases and in the appropriate use of antimicrobials shall also involve livestock keepers. |
25. |
RECOGNISES that health care acquired infections are an important factor in the spread of antimicrobial resistance and in an increased use of antibiotics. |
26. |
STRESSES the importance of effective preventive and hygiene measures, especially hand hygiene and biosecurity measures to prevent and control infections and their spread in both the human health sector and in the veterinary sector. |
27. |
HIGHLIGHTS the importance of international cooperation on AMR, including the work carried out by the World Health Organisation (WHO), the World Organisation for Animal Health (OIE), Codex Alimentarius and the Transatlantic Task Force on Antimicrobial Resistance (TATFAR). |
28. |
WELCOMES the Conference on AMR in Copenhagen on 14-15 March 2012, which provided valuable contributions to the further work to counter AMR through actions against overuse of antimicrobials in humans and animals with a particular focus on CIAs and strengthened surveillance. |
29. |
CALLS UPON THE MEMBER STATES TO:
|
30. |
CALLS UPON THE MEMBER STATES AND THE COMMISSION TO:
|
31. |
CALLS UPON THE COMMISSION TO:
|
(1) 9637/08.
(2) OJ C 302, 12.12.2009, p. 10.
(4) 5427/06 (COM(2005) 684 final) and 8493/10 (COM(2010) 141 final).
(6) EFSA Journal 2009; 7(11):1372, http://ec.europa.eu/health/scientific_committees/emerging/opinions/scenihr_o_026.pdf EMEA/CVMP/447259/2009
(7) P7_TA(2010)0130.
(8) P7_TA(2011)0238.
(9) P7_TA(2011)0473.
(10) 16939/11 (COM(2011) 748).
(11) OJ L 268, 18.10.2003, p. 29.
(12) 16314/11 (C(2011)7660) Commission Recommendation of 27.10.2011 on the research joint programming initiative ‘The Microbial Challenge — An Emerging Threat to Human Health’.
(13) OJ L 92, 7.4.1990, p. 42.
(14) OJ L 136, 30.4.2004, p. 58.